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Cancer is an exceedingly complex disease that is orchestrated and driven by a combination of multiple aberrantly
regulated processes. The nature and depth of involvement of individual events vary between cancer types, and in
lung cancer, the deregulation of the epigenetic machinery, the tumor microenvironment and the immune system
appear to be especially relevant. The contribution of microRNAs to carcinogenesis and cancer progression is well
established with many reports and investigations describing the involvement of microRNAs in lung cancer, however
most of these studies have concentrated on single microRNA-target relations and have not adequately addressed the
complexity of their interactions. In this review, we focus, in part, on the role of microRNAs in the epigenetic regulation
of lung cancer where they act as active molecules modulating enzymes that take part in methylation-mediated
silencing and chromatin remodeling. Additionally, we highlight their contribution in controlling and modulating
the tumor microenvironment and finally, we describe their role in the critical alteration of essential molecules that
influence the immune system in lung cancer development and progression.
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One of the most promising molecular entities to have
impacted cancer research in recent times is the group of
small non-coding RNAs known as microRNAs. Since
the first miRNA gene called lin-4 was discovered in
Caenorhabditis elegans [1], several others have been
identified, and so far over 2500 miRs have been described
in the human genome miRBase (www.mirbase.org) [2].
MicroRNAs have been described to be involved in several
cellular processes including proliferation, development,
metabolism, differentiation and apoptosis. Importantly,
the deregulation of microRNA expression and function
has been linked to many human pathological condi-
tions, including cancer [3,4].* Correspondence: heike.allgayer@medma.uni-heidelberg.de
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unless otherwise stated.Classically, in cancer, microRNAs have been catego-
rized as either oncogenic or tumor suppressor miRNAs.
In the first instance, by post-transcriptionally lowering
mRNA and subsequently protein levels of molecules
with tumor suppressor functions, microRNAs assume an
oncogenic function. Conversely, by targeting oncogenic
molecules, they act as tumor suppressors and the altered
expression levels of the microRNA(s) between tumor
and normal states coupled with the function of the tar-
geted molecule(s) dictate the resulting (end) phenotype.
Beyond the classical regulation of oncogenes and tumor
suppressor mRNAs, aberrantly expressed microRNAs
could in further levels of complexity act: 1) to regulate the
epigenetic machinery by a) directly modulating enzymes
which take part in methylation-mediated silencing and
chromatin remodeling [5] or b) be epigenetically regulated
themselves [6]; 2) in a paracrine fashion via exosomes,
microvesicles and protein complexes to influence the
tumor microenvironment [7-10] and 3) to promote the
release of mediators which activate pro- or anti-cancerhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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microRNA regulation are explained in detail.
MicroRNAs and epigenetic regulation in cancer
The epigenome is both dynamic and highly regulated in
order to conserve normal expression patterns in cells.
One of the most important components of expression
regulation is the methylation of CpG islands within pro-
moter regions both in normal as well as cancer cells
[13,14]. The dynamic balance is maintained by a family
of DNA methyltransferases: notably DNMT1 (mainten-
ance DNMT) and DNMT3a and 3b (de novo DNMTs).
Equally important in epigenetic regulation are covalent
changes in histone tails that are orchestrated by histone
methyltransferases (HMT), histone acetyltransferases
(HAT), histone deacetylases (HDAC) [13,15] and poly-
comb proteins such as PRC 1 and PRC 2 [16]. MicroRNAs
as a part of regulatory networks serve as significant targets
for the epigenetic machinery and are also active players in
modulating enzymes which take part in methylation medi-
ated silencing and the chromatin remodeling machinery.
MiR-127 was the first epigenetically regulated microRNA
to be reported in a cancer entity [17]. Since then, many
microRNAs were found to undergo epigenetic regulation
in different cancer types including colorectal [18,19], uro-
logical [20], breast [21], ovarian [22,23], gastric [24] and
pancreatic [25] as well as different types of haematological
malignancies [26]. Most of the microRNAs are involved in
crucial processes in the cell, thus, a great number of epige-
netically regulated microRNAs (app. 45%) are implicated
in several cancer types (eg., miR −124, −129, −34b at least
7 types, 34a −12 types), however, none of these have so far
been found to be particularly involved in lung cancer [27].
MicroRNAs regulated by methylation
Hypermethylation is one of the most common epigenetic
regulatory mechanisms and about half of the microRNA
genes are subject to hypermethylation of CpG regions of
their promoters [6], resulting in microRNA silencing or
down-regulation. There is ample evidence supporting
this mode of action, for instance, CpG island hyperme-
thylation mediated silencing of miR-124a has been found
in a wide range of lung cancer cell lines, including H358,
CALU3, A549, A427, H2126 and H209. Interestingly,
the epigenetic loss of microRNA-124a was functionally
related to an activation of cyclin D kinase 6 (CDK6) and
an inactivating phosphorylation of the retinoblastoma
tumor suppressor protein (pRb) [28]. A similar type of
regulation was also observed with miR-199a silencing in
several cancer cell lines that occurred as a result of gene
methylation [29]. This microRNA negatively regulates
the proto-oncogene c-Met and its downstream effector
ERK2, thus the hypermethylation of its promoter acts
as an oncogenic switch. Moreover, transfection ofmiR-199a into cancer cells increases their pro-apoptotic
ability, suggesting that miR-199a can be a potential
therapeutic molecule. Ceppi and colleagues discovered
that methylation mediated down-regulation of miR-200c
correlated with a higher invasive potential of NSCLC cell
lines [30] with additional experiments showing inhibition
of in vitro invasion and in vivo metastasis. Accordingly,
miR-200c mimics restored sensitivity to therapeutic com-
pounds such as Cisplatin and Cetuximab. Invariably, an
association between low miR-200c expression, poor grade
differentiation, a higher degree of lymph node affectation
and a lower endogenous E-cadherin expression was ob-
served in a patient cohort. MiR-200c is an important EMT
mediator where it suppresses EMT by down-regulating
ZEB proteins. ZEB1 and ZEB2 proteins are also targets for
miR-141 and miR-429, which have also been shown to be
hypermethylated in lung cancer [31]. In a study by Heller
et al. [32], miR-9-3 and miR-193a were found to be
tumor-specifically methylated in NSCLC patients. More-
over, patients with miR-9-3 methylated NSCLC had a
significantly shorter disease-free survival and shorter
overall survival than the unmethylated control group.
This data supports the idea, that miR-9-3 methylation
could be an interesting prognostic parameter in patients
with NSCLC. In two independent studies, Wang and
colleagues [33] and Watanabe and colleagues [34]
showed that promoter hypermethylation mediated si-
lencing of the miR-34b/c is a common event in NSCLC.
Additionally, Wang et al. showed a strong association
between aberrant methylation of the miR-34b/c gene
and a high probability of relapse, poor overall survival
and disease-free survival in patients with lung cancer.
Furthermore, Watanabe’s study revealed that miR-34b/c
expression negatively correlated with the expression of
c-Met. Similarly, they also showed that the tumor sup-
pressor activity of miR-126 that inhibits invasion by dir-
ectly targeting Crk is silenced in lung cancer cells by the
DNA methylation of its host gene, EGFL7. Interestingly,
it was also shown that the promoter methylation status of
the miR-503 gene may influence sensitivity of NSCLC cells
to cisplatin, suggesting that epigenetic interference might
be a promising way to improve existing therapies [35].
Taken together, the hypermethylation of microRNA
genes or promoter sequences is an important mechanism
leading to the down-regulation of microRNA expression
resulting in a reversal of oncogene suppression (c-Met,
CDK6, Crk), repression of tumor suppressor genes
(pRB), or activation of proteins involved in epithelial-to-
mesenchymal transition (EMT) (ZEB1/2). However, the
converse is also true, for instance, the high expression
of miR-196a in lung cancer samples and cell lines was
attributed to DNA demethylation [36]. Moreover, miR-
196a up-regulation correlated with a more advanced
clinical stage and lymph node metastasis in lung cancer.
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miR-196a expression levels promote cell proliferation,
migration and invasion by targeting and suppressing the
homeobox protein -A5 (HOXA5) at the protein as well
as at the mRNA level. An inverse relation was then
demonstrated in NSCLC tissues.
MicroRNAs regulated by histone modifications
Aside methylation changes, histone modifications have
also been implicated in the regulation of microRNA ex-
pression. Incoronato and colleagues [37] investigated the
mechanism behind miR-212 silencing in lung cancer and
by comparing Calu-1 (lung cancer cell line) and MRC5
(human fibroblasts), they found significant differences in
the methylation status of H3K27 and H3K9 marks and
in the acetylation status of H3K9, suggesting that modi-
fications of histones on the miR-212 gene predicted
transcriptional start sites contributing to its strong
down-regulation in lung cancer. Additionally, an ana-
lysis of human tissue specimens of normal tissue and
lung cancer revealed a correlation between miR-212
silencing and up-regulation of anti-apoptotic protein
PED. Similarly, miR-373 silencing in lung cancer was
found to be deacetylase-dependent with consequences
on cell proliferation, migration, invasion and the ex-
pression of mesenchymal markers that appear to be
modulated through IRAK2 and LAMP1 [38].
Interestingly, instances exist where certain microRNAs
that have been established as key players in several can-
cer types including lung cancer [39], have been found to
be regulated by epigenetic mechanisms in some of these
tumor entities, but not in lung cancer. This is the case
with miR-155, which in addition to being one of the
most consistently regulated microRNAs in lung cancer,
has equally significant prognostic significance [40,41].
Whereas miR-155 was found to be repressed by deacety-
lation of H2A and H3 through a mechanism mediated
by BRCA1 in breast cancer [42], such reports are lacking
in lung cancer, even though BRCA1 is not that unim-
portant in lung cancer [43].
MicroRNAs regulating the epigenetic
machinery – Epi-microRNAs
MicroRNAs can also act as modifiers of the epigenetic
network. These so-called epi-microRNAs contribute to
altered epigenomic patterns in cancer cells, with the first
evidence of such microRNA activity observed in lung
cancer cell lines, where the miR-29 family (29a, 29b and
29c) was found to directly target the de novo DNA methyl-
transferases, DNMT-3a and DNMT-3b, inhibiting their
activity. Consequently, this action resulted in a re-
activation of silenced tumor suppressor genes (FHIT,
WHOX), thus preventing tumor progression [5]. How-
ever, in contrast to the large number of studies conductedin different cancer types, very few reports exist on
microRNAs that regulate the epigenome in lung cancer.
Of the studies documented in lung cancer, was one
where Xi et al. reported that the repression of miR-487b
in cultured cells exposed to cigarette smoke, and in pri-
mary lung cancers correlated with an overexpression of
the polycomb repressor proteins BMI1 and SUZ12 [44].
Interestingly, this state coincided with miR-487b gene
methylation and de novo nucleosome occupancy in its
area, indicating that the microRNA also epigenetically
regulated itself. Besides its function of epigenetic regu-
lation, miR-487b also directly targets WNT5A, KRAS
and MYC, suggesting a multiple mode of action. An-
other exciting example of the regulatory role of micro-
RNAs in lung cancer epigenetics involves miR-449 [45].
This study showed that the down-regulation of miR-449
might be responsible for an overexpression of HDAC1,
subsequently inhibiting cell growth and promoting
tumor suppression. Similar work by Jeon and colleagues
also revealed a therapeutic potential for miR-449, show-
ing that co-treatment with miR-449 and a HDAC1 in-
hibitor led to significantly higher growth reduction than
with the HDAC1 inhibitor itself. Further examples dem-
onstrating this regulatory principle include the work
done by Cho and colleagues [46] where they showed
that the down-regulation of miR-101 affected enhancer
of zeste homolog 2 (EZH2), a member of the polycomb
repressive complex causing its overexpression. EZH2 is
known to be involved in the methylation of H3K27,
bringing about gene silencing and in the process regu-
lating several cancer-associated processes. They found
that the general methylation status of H3K27 was
significantly higher in metastatic lung cancer than in
primary lung cancer tissue, with in vitro studies showing a
significant impact on invasion. Furthermore, EZH2 was
also shown to be a direct target of miR-138 [47] where
experiments on several lung cancer cell lines, as well as
tissue samples from patients with NSCLC revealed that
the down-regulation of miR-138 resulted in an up-
regulation of EZH2 inhibiting apoptosis, G0/G1 cell
cycle arrest and promoting cell proliferation and tumor
invasion. A summary of microRNAs involved in epigen-
etic regulation are presented in Table 1.
MicroRNAs and the tumor microenvironment
The tumor microenvironment is an increasingly appreci-
ated item of interest in cancer development and progres-
sion. During cancer progression, sequences of molecular
changes arise in the tumor as well as in the neighboring
tissue stroma. Since tumor development is driven by
physiological responses to an aberrant stromal environ-
ment [48] the interaction between the tumor and stromal
cells determines the outcome of progression [49]. The
tumor microenvironment is a complex structure that in
Table 1 MicroRNAs involved in epigenetic regulatory mechanisms in lung cancer
MicroRNA Chromosome Type of regulation Target Functional consequence References
miR-124a-1 8 Hypermethylation mediated silencing CDK6 Oncogene activation, repression of tumor suppression Lujambio et al., 2007 [28]
miR-124a-2 8 pRb
miR-124a-3 20
mir-199a-1 19 Hypermethylation mediated silencing c-Met Anti-apoptotic function Kim et al., 2008 [29]
mir-199a-2 1 (ERK2) Oncogene activation
miR-200c 12 Hypermethylation mediated down-regulation ZEB1 Promotion of EMT and metastasis Ceppi et al., 2010 [30]
miR-141 12 Hypermethylation ZEB1/2 Lopez Serra; Esteller, 2012 [31]
miR-429 1 Hypermethylation ZEB1/2 Lopez Serra; Esteller 2012 [31]
miR-9-3 15 Methylation mediated down-regulation Heller et al., 2012 [32]
miR-193a 17 Methylation mediated down-regulation Altered expression regulation of genes involved in
Proliferation, apoptosis, differentiation and adhesion
Heller et al., 2012 [32]
miR-34b/c 11 Promoter hypermethylation mediated silencing (c-Met) Oncogene activation, metastasis formation Wang et al., 2011 [33]
Watanabe et al., 2011 [34]
miR-503 X Promoter methylation mediated silencing FANCA Modulate sensitivity to cisplatin regulate apoptosis Li et al., 2014[35]
miR-126 9 Host gene promoter methylation mediated
silencing
Crk Oncogene activation Watanabe et al., 2011 [34]
miR-196a-1 17 Demethylation mediated up-regulation HOXA5 Promotion of cell proliferation, migration and invasion. Liu Xiang-hua et al., 2012 [36]
miR-196a-2 12
miR-212 17 Histone tail methylation mediated down-regulation PED Anti-apoptotic function Incoronato et al., 2011 [37]
miR-373 19 Histone acetylation mediated silencing IRAK2 Promotion of cell proliferation, migration, and invasion,
Pro-EMT function
Seol et al., 2014 [38]
LAMP1
miR-29a 7 MicroRNA’s downregulation mediates DNMT DNMT3a Repression of tumor suppression Fabbri et al., 2007 [5]
miR-29b-1 7 Up-regulation DNMT3b
miR-29b-2 1 (FHIT
miR-29c 1 WHOX)




Promotion of tumor progression and metastasis Xi et al.,2013 [44]
miR-449 5 MicroRNA’s down-regulation mediates HDAC1 HDAC1 Repression of tumor suppression Jeon et al., 2011 [45]
Up-regulation Promotion of tumor metastasis
miR-101-1 1 MicroRNA’s down-regulation mediates EZH2 EZH2 Promotion of EMT and tumor metastasis Cho et al., 2011 [46]
miR-101-2 9 Up-regulation (CDH1, MMP-2)
miR-138-1 3 MicroRNA’s down-regulation mediates EZH2 EZH2 Promotion of proliferation, repression of apoptosis,
Disruption of cell cycle arrest
Zhang et al., 2013 [47]
miR-138-2 16 Up-regulation
A compilation of the most significant microRNAs targeted by epigenetic regulatory mechanisms, including those that modulate epigenetic changes in lung cancer. The most important functional outcomes are
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many other cell types, including endothelial cells, inflam-
matory cells and most abundantly, fibroblasts [50]
While normal fibroblasts have been found to prevent
tumor progression [51] the so-called cancer associated
fibroblasts (CAFs) generate an environment promoting
tumor growth and invasiveness [52]. CAFs are character-
ized by specific changes in their secretory profile, e.g, che-
mokines that attract inflammatory cells. Together, they
release growth factors that trigger cancer cell proliferation,
inhibit apoptosis or indirectly stimulate angiogenesis [53].
Interestingly, one of the major mechanisms by which
CAFs are activated is mediated by specific microRNAs,
e.g. miR-21, miR-31, −214, and 155 [7,8]. There is ample
evidence, that microRNAs are not only present in the
cells, but also in extracellular space [54,55]. Importantly,
extracellular microRNAs also play a very vital role in cell
to cell communication [9] and are capable of contributing
to microenvironment-associated processes such as angio-
genesis, matrix degradation and stromal remodeling, all
which support cancer progression and metastasis [10].
About 90% of microRNAs found in the ECM are bound
to RNA- binding proteins (eg. AGO proteins, especially
Ago2, NPM1 - nucleoplasmin 1 and GW 182 responsible
for microRNA stabilization as well as secretion) and just
10% exist in extracellular vesicles such as exosomes,
apoptotic bodies and, mainly microvesicles (MVs)
[9,55,56]. Remarkably, most of the microRNAs that are
differentially expressed in CAFs are down-regulated as
compared with normal fibroblasts, suggesting that they
act as suppressors of stromal activation [57]. Evidence
for the contribution of microRNAs in lung cancer
angiogenesis arising from a specific influence on the
tumor microenvironment was hinted at in the study by
Jusufovic and colleagues [58] who found significantly
higher microvessel density (MVD) together with de-
creased expression levels of let-7b and miR-126 in
tumor and surrounding tissue of 50 NSCLC patients as
compared to corresponding normal tissues. Interest-
ingly, there was no difference in expression between
tumor and surrounding tissue for both microRNAs and
MVD, indicating similar molecular changes in the
tumor and surrounding cells in this context [58].
In addition to influencing the local microenviron-
ment, tumor cells have also been shown to secrete exo-
somes at a significantly higher level compared to normal
cells [59]. These so-called tumor-derived exosomes (TD
exosomes) contain pro-tumorigenic components, in par-
ticular abundant microRNAs which influence and modify
stromal cells and recruit them as cancer-associated stro-
mal cells, which in turn influence cancer cells and the
ECM contributing to cancer development and progression
[10,59]. Additionally, a mechanism based on passive
leakage has been proposed, in which microRNAs arereleased from the cells due to injury, chronic inflamma-
tion, necrosis, or from cells with very short half-lives, like
platelets [60].
Notable instances of microRNA regulation of the
tumor microenvironment in lung cancer include the
repression of the angiogenic program by IL-8, ICAM
and CXCL1 through the lung tumor cell mediated exo-
somal release of miR-192 with a consequent reduction
in metastatic burden and tumor colonization [61]. In
another study, TGF-β induced release of miR-183 by
lung cancer cells was found to control DAP12, a critical
stimulatory signal adaptor linked to numerous NKC re-
ceptors resulting in a suppression of NK cell function
[62]. Still, Krysan and colleagues found the inflammatory
molecule, prostaglandin E2 (PGE2) to mediate an up
regulation of c-Myc in stromal cells, which in turn mod-
ulates the expression of the miR-17-92 cluster, that
effectively targets the tumor suppressor PTEN. The end
effect was an augmentation of apoptosis resistance in
non-small cell lung cancer (NSCLC) cells [63]. In what
appears to be an interesting example of the microenvir-
onment of one organ affecting the dissemination of cells
from a different organ, Subramani et al., found that miR-
768-3p released by brain astrocytes targets K-ras, miti-
gating metastatic potential of lung cancer cells. The
down-regulation of this microRNA seen in many brain
tumors is thought to enhance K-ras expression, includ-
ing its downstream effectors ERK1/2 and B-Raf, and
thus promoting metastasis [64].
MicroRNAs and immune responses in lung cancer
In addition to the processes described above, it has be-
come increasingly clear that microRNAs play multiple
roles in the negative regulation of numerous immune re-
sponses triggered by rapidly proliferating neoplastic cells.
The genetic instability of neoplastic cells is associated
with alterations of antigenic patterns that may in turn
lead to attenuated recognition of the tumor by immune
cells [65]. Some of these alterations are largely influ-
enced by actions mediated by a constellation of different
microRNAs (Figure 1). An example of this is miR-9 that
is over-expressed in many cancers including lung cancer
[66]. MiR-9 is capable of down-regulating the transcrip-
tion of the MHC class I gene, thereby preventing the
recognition of tumor cells by the immune system
[11,56]. On the other hand, a down-regulation of miR-29
expression in cancer leads to an up-regulation of B7-H3
gene transcription and the subsequent expression of this
molecule on the surface of neoplastic cells [67]. Conse-
quently, B7-H3 delivers an inhibitory signal to T cells
and NK cells and therefore inhibits the anti-tumor activ-
ity mediated by these cells [68,69]. Similarly, miR-222
and −339 down-regulate the expression of intracellular
cell adhesion molecule 1 (ICAM-1) on the surface of
Figure 1MicroRNA-mediated regulation of tumor microenvironment. The scheme demonstrates involvement of microRNAs in chemokine-mediated
recruitment of regulatory T cells, monocytes, macrophages and MSCs and the role of microRNAs in tumor-related dysfunction of NK and cytotoxic T cells.
All microRNAs are shown in red while gene targets and types of responses are shown in black. Arrows indicate directions of cause-and-effect relationships.
Rusek et al. Molecular Cancer  (2015) 14:34 Page 6 of 10tumor cells [70]. The binding of ICAM - to lymphocyte
function-associated antigen (LFA-1) has been shown to
be essential for optimal activation of cytotoxic T cell
(CTLs) [71], thus, miR-222 and −339 in cancer cells
contribute to impaired CTL-mediated tumor cell lysis
[70]. Moreover miRs-221 and −222 are overexpressed in
NSCLC and act in part by targeting TIMP3 [72] which
has known functions in controlling cytokine and growth
factor homeostasis. Furthermore, several microRNAs,
for instance miRs-21 and −126/126*, contribute to the
modulation of the tumor microenvironment, which en-
compasses not only stroma cells but also soluble factors
and signaling molecules [73-76] (Figure 1). Regulatory T
lymphocytes (Tregs), are important components of the
tumor stroma, and are known to predominantly exert
immunosuppressive effects. A number of tumor-bound
chemokines including CCL22 have been shown to re-
cruit Tregs to modulate immune responses in cancer
[77]. Notably, CCL22 production in cancer cells is regu-
lated by miR-34a, which suppresses the expression of
this chemokine. On the other hand, increased levels of
TGF-β in the tumor milieu down-regulate the expres-
sion of miR-34a and thereby increase infiltration of im-
munosuppressive Tregs. The TGF-β - miR-34a - CCL22
axis is therefore important in modulating the tumor micro-
environment [78]. Other chemokines such as CXCL12
(Sdf-1) and CCL2 (MCP-1) are secreted by various cancer
types and function as autocrine growth factors as well
as chemo-attractants for progenitor cells and mono-
cytes/macrophages [12,79,80]. Interestingly, the tran-
scription of the CXCL12 gene is controlled by miR126/miR126*. This microRNA pair directly inhibits the ex-
pression of CXCL12 and down-regulates the production
of CCL2 in a CXCL12-dependent process in which stro-
mal cells (mainly mesenchymal stem cells, MSCs) seem
to play the crucial role. In cancer cells, decreased miR-
126/126* expression results in an increased production
and secretion of CXCL12 that in turn attracts MSCs to
the tumor microenvironment and increases the secre-
tion of CCL2 [75]. Subsequently, CCL2 recruits mono-
cytes/macrophages to the site of neoplastic growth [81].
During migration, monocytes are exposed to many sig-
nals derived from cancer and stromal cells that induce
their differentiation towards classically (M1) or alterna-
tively activated (M2) macrophages. Tumor associated
macrophages (TAMs) control the majority of immuno-
logical processes within tumors exerting both, regressive
(M1) or progressive (M2) effects on the tumor develop-
ment [82,83]. Unfortunately, the vast majority of TAMs
exhibit an M2-like phenotype. Remarkably, a significant
number of microRNAs like miRs-9, −21 and −146 are
involved in the differentiation of the TAMs from periph-
eral blood monocytes (Figure 2). Both monocytes/macro-
phages and cancer cells are capable of releasing different
pro- and anti-inflammatory cytokines like the immuno-
suppressive cytokine IL-10, which fosters tumor growth
[84]. Substantial amounts of this cytokine are secreted by
neoplastic cells including that of the lung [85,86]. Interest-
ingly, the transcription of the IL-10 gene in tumor cells is
indirectly regulated by miR-30d, which acts by directly
repressing GALNT7. GALNT7 suppression leads to in-
creased production and secretion of IL-10, which in turn
Figure 2 MicroRNA-mediated control of monocyte differentiation and tumor associated macrophages (TAMs) functions. All microRNAs
are shown in red while gene targets and types of responses are shown in black. Arrows indicate directions of cause-and-effect relationships.
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phenotype [87]. In addition, in human monocytes, IL-10
up-regulates miR-187 expression which down-regulates
TNF-α production. Moreover, in macrophages, miR-187
indirectly decreases the expression of IL-6 and IL-12p40
via decreasing MAIL in an NFKBIZ-dependent manner
[88]. Along similar lines, the differentiation of monocytes
towards M2 macrophages can be induced by M-CSF. M-
CSF signaling down-regulates miR-142-3p in monocytes
which leads to increased Egr2 (Krox20) expression. This
transcription factor can control differentiation of mono-
cytes via activating macrophage-specific genes such as
C-FMS, acting in cooperation with Spi-1/PU.1 [89].
Many of the pro-tumorigenic outcomes of TAMs’ are
controlled by microRNAs and depend on such factors
like HMGB1 and IL-10 [88,90]. These mediators are
secreted both by tumor cells and stroma and act via
interactions with several cell surface receptors including
toll-like receptors (TLR) and the IL-10 receptor. TLR2-,
TLR-4- and TLR5-mediated signaling and NF-κβ activa-
tion in macrophages up-regulates the expression of miR-
146 that in turn targets IRAK1 and TRAF6, proteins
which are crucial components of interleukin-1- and
TNF-related signaling pathways, respectively. More spe-
cifically, miR-146 acts via targeting IRAK1 and TRAF6,
members of the TLR-NF-κβ pathway, and therefore
contributes to controlling the expression of an array of
inflammatory cytokine genes. MiR-146 therefore acts
through a negative feedback loop and down-regulates
cytokine signaling [91]. On another note, miR-92 isup-regulated following TLR-4 activation and in turn
down-regulates the expression of TNF-α and IL-6 [92].
TLR4-mediated up-regulation of miR-21 suppresses pro-
grammed cell death protein-4 (PDCD4) expression. This
mechanism may limit pro-inflammatory cytokine pro-
duction in macrophages via suppressing NF-κβ activa-
tion, leading to an increased IL-10 production [90].
Notably, miR-21 and miR-29a are expressed at different
levels in various cancers including lung cancer [93-95].
Both miR-21 and miR29a can act within cancer cells or
can be delivered from cancer cells to macrophages by
microvesicles and can subsequently bind intracellular
TLR7 or TLR8. This microRNA-TLR interaction leads to
the activation of the NF-κβ pathway and an increase in the
production of the pro-inflammatory cytokines, IL-6 and
TNF-α that in turn activate pro-metastatic responses in
TAMs [96]. Some microRNAs also mediate a cross talk be-
tween cancer and stromal cells as in the case of TAM-
derived miR-223, which down-regulates Mef2c expression
in neoplastic cells, leading to an increase of cancer cell inva-
sion, probably through the involvement of the miR-223 –
Mef2c – β-catenin pathway [97].
Taken together, substantial evidence supports the dy-
namic role of microRNAs within the tumor microenvir-
onment and with the immune system culminating in the
promotion of tumor growth and immune evasion.
Conclusion
The role of microRNAs in the development and progres-
sion of lung cancer as well as other types of cancers is
Rusek et al. Molecular Cancer  (2015) 14:34 Page 8 of 10overwhelming; with several reports demonstrating the
enormous impact microRNAs have on several cancer-
associated processes.
In this review, we have elaborated on how microRNA-
target interactions transcend beyond simple post-
transcriptional regulation of oncogenes and/or tumor
suppressor mRNAs to a more complex setting where
they not only modulate networks and pathways, but also
affect the tumor microenvironment, the epigenome and
immune evasion. In lung cancer, their impact is very
relevant, and to a large degree is deeply entrenched in
several cascades, which impact lung cancer progression
and metastasis. Inherently, microRNAs can target sev-
eral molecules concurrently, and using this advantage
together with the identification of the right molecule in
the right context could have great potential, especially
when used alongside other therapeutic modalities. Their
involvement in several critical cancer associated pro-
cesses makes them highly interesting molecules. Their
effects transcend simple intracellular events, and are
able to influence neighboring cells and even those at
distant sites. Sufficient evidence indicates that they are
significant modulators of our immune system which
widens their scope as potential therapeutic agents.
Despite the tremendous amount of knowledge we have
already on microRNAs, new publications keep coming
out, describing yet other novel functions, making us
marvel about the wide-reaching potential of these small
molecules. In summary, microRNAs seem to be a very
promising research target, however, the complexity of
their actions makes keeping this promise very challenging.
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